COVID-19 tagged posts

COVID-19, the disease resulting from SARS-CoV-2 infection, is associated with highly variable clinical outcomes that range from asymptomatic disease to death. For those with milder infections, COVID-19 can produce respiratory infection symptoms (cough, congestion, fever) and sensory phenotypes such as headache and loss of sense of smell.

In more severe cases, SARS-CoV-2 infection can affect nearly every organ and result in strokes from vascular occlusion, cardiovascular damage and acute renal failure. A substantial number of actively infected patients suffering from both mild and severe infections experience sensory-related symptoms, such as headache, visceral pain, Guillain-Barre syndrome, nerve pain and inflammation...

A team led by researchers at Weill Cornell Medicine, the University of Wisconsin-Madison; Scripps Research and the University of Chicago has identified an antibody that appears to block infection by all dominantvariants of the virus that causes COVID-19, including Omicron, the most recent. Their discovery could lead to more potent vaccines and new antibody-based treatments.

In a study published March 6 in the Journal of Clinical Investigation, senior author Dr. Patrick Wilson, the Anne E...

Scientists working in the School of Biochemistry and Immunology in the Trinity Biomedical Sciences Institute at Trinity College Dublin have made an important breakthrough in understanding what goes wrong in our bodies during the progression of inflammatory diseases and – in doing so – unearthed a potential new therapeutic target.

The scientists have found that an enzyme called Fumarate Hydratase is repressed in macrophages, a frontline inflammatory cell type implicated in a range of diseases including Lupus, Arthritis, Sepsis and COVID-19.

Professor Luke O’Neill, Professor of Biochemistry at Trinity is the lead author of the research article that has just been published in leading international journal, Nature. He said:

“No-one has made a link from Fumarate Hydratase to infla...

Older people who were infected with COVID-19 show a substantially higher risk — as much as 50% to 80% higher than a control group — of developing Alzheimer’s disease within a year, according to a study of more than 6 million patients 65 and older.

In a study published today in the Journal of Alzheimer’s Disease, researchers report that people 65 and older who contracted COVID-19 were more prone to developing Alzheimer’s disease in the year following their COVID diagnosis. And the highest risk was observed in women at least 85 years old.

The findings showed that the risk for developing Alzheimer’s disease in older people nearly doubled (0.35% to 0.68%) over a one-year period following infection with COVID...